title: Identification of prognostic factors in patients with diffuse large B-cell lymphoma.
abstract: To identify prognostic factors for patients with diffuse large B-cell lymphoma (DLBCL), specifically those classified into conflicting subgroups by Hans' and Choi's classification algorithms. We retrospectively reviewed clinical and pathological data of 154 patients diagnosed with de novo DLBCL in the First Hospital of Jilin University from January 2004 to September 2011. All cases were classified into subgroups based on Hans' and Choi's algorithms with immunohistochemical markers.
  
  
  METHODS
  The correlation between various clinicopathological factors and 5-year survival rate, the correlation between those factors with the International Prognostic Index, the concordance between Hans' and Choi's approach was evaluated. The survival in different subtypes as classified by Hans' or Choi's approach was mapped.
  
  
  RESULTS
  The Eastern Cooperative Oncology Group (ECOG) performance score 2-5, positive Bcl-2 expression, negative CD10 expression or negative Bcl-6 expression significantly correlated with worse prognosis. The two algorithms showed good consistency (83% concordance, Kappa = 0.660, P < 0.001). By both classifications, the 5-year overall survival rate in germinal center B-cell-like subtype (GCB) lymphoma is significantly higher than that in the non-GCB subtype. There were 25 cases assigned to conflicting subtypes by the two approaches. Among these 25 cases, ECOG 2-5, positive Bcl-2 expression, negative CD10 expression, or negative Bcl-6 expression significantly correlated with worse prognosis.
  
  
  CONCLUSIONS
  ECOG 2-5, positive Bcl-2 expression, negative CD10 expression, or negative Bcl-6 expression are independent markers for poor prognosis of DLBCL patients. There were 15% cases assigned to conflicting subgroups based on the two algorithms. For these cases, ECOG 2-5, positive Bcl-2 expression, negative CD10 expression, or negative Bcl-6 expression still significantly correlate with poor prognosis.
authors.affiliation: Department of Pathology, The First Hospital of Jilin University, Changchun, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Peng
authors.affiliation: Department of Pathology, The First Hospital of Jilin University, Changchun, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Guo
authors.affiliation: Department of Pathology, The First Hospital of Jilin University, Changchun, China.
authors.forename: Wei-Kai
authors.initials: WK
authors.lastname: Yao
authors.affiliation: Department of Pathology, The First Hospital of Jilin University, Changchun, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zheng
authors.affiliation: Department of Pathology, The First Hospital of Jilin University, Changchun, China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Pathology, The First Hospital of Jilin University, Changchun, China.
authors.forename: Xiu-Mei
authors.initials: XM
authors.lastname: Duan
authors.affiliation: Department of Pathology, The First Hospital of Jilin University, Changchun, China.
authors.forename: Yin-Ping
authors.initials: YP
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000032:analysis*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D015260:Neprilysin / Q000032:analysis; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D051560:Proto-Oncogene Proteins c-bcl-6 / Q000032:analysis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: C084103:BCL6 protein, human; D015415:Biomarkers; D019253:Proto-Oncogene Proteins c-bcl-2; D051560:Proto-Oncogene Proteins c-bcl-6; D015260:Neprilysin